Tandem Diabetes Care, Inc. (TNDM) — Analyst outlook / Analyst consensus target is. Based on 39 analyst ratings, the consensus is bullish — 24 Buy, 15 Hold.
The consensus price target is $30.50 (low: $21.00, high: $56.00), representing an upside of 44.5% from the current price $21.11.
Analysts estimate Earnings Per Share (EPS) of $-1.69 and revenue of $0.91B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.47 vs est $-1.69 (beat +13%). 2025: actual $-3.04 vs est $-2.09 (missed -45.8%). Analyst accuracy: 77%.
TNDM Stock — 12-Month Price Forecast
$30.50
▲ +44.48% Upside
Average Price Target
Based on 39 Wall Street analysts offering 12-month price targets for Tandem Diabetes Care, Inc., the average price target is $30.50, with a high forecast of $56.00, and a low forecast of $21.00.
The average price target represents a +44.48% change from the last price of $21.11.
Highest Price Target
$56.00
Average Price Target
$30.50
Lowest Price Target
$21.00
TNDM Analyst Ratings
Buy
Based on 39 analysts giving stock ratings to Tandem Diabetes Care, Inc. in the past 3 months
EPS Estimates — TNDM
77%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$1.47
vs Est –$1.69
▲ 14.9% off
2025
Actual –$3.04
vs Est –$2.09
▼ 31.4% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — TNDM
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.940B
vs Est $0.908B
▲ 3.4% off
2025
Actual $1.015B
vs Est $1.001B
▲ 1.3% off
Revenue Trend
Revenue has been relatively flat. Analysts forecast revenue contraction ahead.
